Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kiora Pharmaceuticals ( (KPRX) ) has provided an announcement.
On April 1, 2026, Kiora Pharmaceuticals announced that Chief Development Officer Eric J. Daniels, M.D., MBA, had submitted his resignation, effective April 17, 2026, to pursue another opportunity. The company said his departure, disclosed publicly on April 2, 2026, did not stem from any disagreement over operations, policies, or practices, and it has launched a search for his successor.
Management emphasized that Kiora’s clinical operations remain on track, with its internal team and external CRO network continuing to drive enrollment in the ABACUS-2 Phase 2 trial of KIO-301 and the KLARITY Phase 2 trial of KIO-104. Following prior safety reviews, ABACUS-2 has been cleared to complete enrollment in the 50µg cohort and to begin the 100µg cohort, while all safety checkpoints have been cleared in KLARITY and patient enrollment is ongoing, underscoring continuity in the company’s development pipeline despite the leadership change.
The most recent analyst rating on (KPRX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Kiora Pharmaceuticals stock, see the KPRX Stock Forecast page.
Spark’s Take on KPRX Stock
According to Spark, TipRanks’ AI Analyst, KPRX is a Neutral.
The score is primarily held down by weak TTM financial performance (zero revenue, sizable losses, and heavy cash burn). Technicals also lean bearish with the stock below key moving averages and negative MACD. Valuation further pressures the score due to a very high P/E and no dividend support.
To see Spark’s full report on KPRX stock, click here.
More about Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing advanced small-molecule therapies for retinal diseases. Its pipeline includes KIO-301, a molecular photoswitch initially targeting retinitis pigmentosa with potential in choroideremia and Stargardt disease, and KIO-104, a next-generation non-steroidal DHODH inhibitor for macular edema due to retinal inflammation.
The company targets critical pathways underlying retinal degeneration with the aim of slowing, stopping, or restoring vision loss in inherited and age-related retinal conditions. Kiora leverages an internal clinical development team supported by a network of contract research organization partners to advance its Phase 2 programs and maintain enrollment momentum across its key trials.
Average Trading Volume: 47,157
Technical Sentiment Signal: Sell
Current Market Cap: $7.7M
For a thorough assessment of KPRX stock, go to TipRanks’ Stock Analysis page.